News First human trial backs AI-designed 'universal' vaccine An AI-powered universal vaccine tech developed by UK biotech DIOSynVax has shown preliminary efficacy in a world-first human trial.
News Parabilis prices IPO at an ambitious $475 million Parabilis has set the terms of its IPO, seeking to raise a hefty $475m for phase 3 trials of its lead drug for desmoid tumours.
News ADC Therapeutics slumps on cancer drug safety scare Shares in ADC Therapeutics fell more than 50% after a non-Hodgkin lymphoma trial showed more deaths with its Zynlonta drug compared to a control.
News Meet Dalton, a new AI-powered drug discovery platform Just a few months after emerging from stealth, the UK's DaltonTx has launched its AI in drug discovery platform and revealed its first client.
News EULAR 26 hears of treatment advances in lupus Three trials of potentially first-in-class therapies for J&J, UCB/Biogen, and Merck KGaA at EULAR have offered hope of new targeted drugs for lupus.
News £600m funding call opens for UK biomedical research centres £600m in funding is being allocated for an expansion in the network of biomedical research centres, a pillar of the UK's life sciences strategy.
Oncology ASCO 2026: All about DNA damage response, with Luke Piggot Luke Piggot, a principal scientist at Debiopharm, shares some recent data and news about the company's work in DNA damage repair inhibitors.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
